Enzon Pharmaceuticals Reports Significant 2025 Net Loss Amidst Transformational Merger with Viskase

summarizeSummary

Enzon Pharmaceuticals reported a significant net loss in 2025, driven by merger-related expenses, as it progresses with a transformational merger with Viskase that will result in a 1-for-100 reverse stock split and overwhelming control by Icahn affiliates.

check_boxKey Events

• Transformational Merger with Viskase

  Enzon Pharmaceuticals is set to merge with Viskase Companies, Inc., becoming 'Viskase Holdings, Inc.' Viskase stockholders will hold 55% of the combined company, fundamentally changing Enzon's business from a shell entity.

• Significant Net Loss in 2025

  The company reported a net loss of $3.409 million for the year ended December 31, 2025, a sharp decline from a net income of $0.778 million in 2024, largely due to $3.955 million in merger-related transaction expenses.

• Planned 1-for-100 Reverse Stock Split

  Stockholders have approved a 1-for-100 reverse stock split, which will be implemented prior to the completion of the merger, significantly reducing the number of outstanding common shares.

• Overwhelming Control by Icahn Affiliates Post-Merger

  Icahn Enterprises Holdings L.P. and its affiliates are projected to beneficially own approximately 93.32% of the outstanding shares of the combined company following the merger, concentrating control.

auto_awesomeAnalysis

This annual report details Enzon Pharmaceuticals' financial performance for 2025 and provides a comprehensive update on its pending merger with Viskase Companies, Inc. The company reported a substantial net loss of $3.409 million in 2025, a significant deterioration from a net income of $0.778 million in 2024, primarily due to $3.955 million in transaction expenses related to the merger. The filing confirms that Enzon, currently operating as a public company acquisition vehicle with no clinical operations and limited revenue, is set to merge with Viskase, with Viskase stockholders holding 55% of the combined entity. A 1-for-100 reverse stock split has been approved and will be effected prior to the merger. Notably, Icahn Enterprises Holdings L.P. and its affiliates are expected to hold approximately 93.32% of the combined company, indicating highly concentrated ownership. The company's liquidity is tied to the merger, with existing cash sufficient only through March 2027 if the transaction is not completed. This filing is critical as it outlines the company's dire financial state and the transformational, albeit highly dilutive and control-shifting, path forward through the merger.